Dimensional Fund Advisors
VTGN icon

Dimensional Fund Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Dimensional Fund Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,874
Closed -$101K – 3301
2025
Q4 		$101K Buy
151,874
+83,857
+123% +$303K ﹤0.01% 3147
2025
Q3 		$241K Buy
68,017
+24,655
+57% +$73.7K ﹤0.01% 3096
2025
Q2 		$86.7K Buy
43,362
+25,817
+147% +$58.6K ﹤0.01% 3195
2025
Q1 		$43.9K Buy
+17,545
New +$49.7K ﹤0.01% 3265

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors's VTGN Position: Q1 2026 in Review

Dimensional Fund Advisors sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 151,874 shares — an estimated $101K sold.

Dimensional Fund Advisors first reported a position in VTGN in Q1 2025 and held it in 4 quarters. The position peaked at $241K in Q3 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Dimensional Fund Advisors reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 151,874 VistaGen Therapeutics shares in Q1 2026, an estimated $101K.
  • Dimensional Fund Advisors first reported a position in VistaGen Therapeutics in Q1 2025 and held it in 4 quarters.
  • Dimensional Fund Advisors's VistaGen Therapeutics position peaked at $241K in Q3 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.